Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Clinically relevant molecular pathological diagnostics in breast cancer].
Rodepeter FR, Teply-Szymanski J, Romey M, Grass A, Erber R, Lebeau A, Mack EKM, Tarawneh TS, Gremke N, Boekhoff J, Wündisch T, Wagner U, Jank P, Denkert C. Rodepeter FR, et al. Among authors: jank p. Pathologie (Heidelb). 2023 Feb;44(1):39-49. doi: 10.1007/s00292-022-01175-0. Epub 2023 Jan 11. Pathologie (Heidelb). 2023. PMID: 36629894 Review. German.
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Loibl S, et al. Among authors: jank p. Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12. Clin Cancer Res. 2019. PMID: 30979740
What turns CREB on? And off? And why does it matter?
Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, Seliger B. Steven A, et al. Among authors: jank p. Cell Mol Life Sci. 2020 Oct;77(20):4049-4067. doi: 10.1007/s00018-020-03525-8. Epub 2020 Apr 28. Cell Mol Life Sci. 2020. PMID: 32347317 Free PMC article. Review.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, Jank P, Sinn HP, Huober J, Becker C, Blohmer JU, Marmé F, Schmitt WD, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching PA, Jackisch C, Untch M, Schneeweiss A, Loibl S. Karn T, et al. Among authors: jank p. Ann Oncol. 2020 Sep;31(9):1216-1222. doi: 10.1016/j.annonc.2020.05.015. Epub 2020 May 24. Ann Oncol. 2020. PMID: 32461104 Free article.
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Jank P, et al. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020. PLoS One. 2020. PMID: 32841306 Free PMC article.
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆.
Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, Sinn HP, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt WD, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn JZ, Schem C, Sinn BV, Soon-Shiong P, van Mackelenbergh M, Fasching PA, Rabizadeh S, Loibl S. Denkert C, et al. Among authors: jank p. Ann Oncol. 2021 Apr;32(4):500-511. doi: 10.1016/j.annonc.2020.12.016. Epub 2021 Jan 6. Ann Oncol. 2021. PMID: 33418062 Free article.
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V. Llop-Guevara A, et al. Among authors: jank p. Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11. Ann Oncol. 2021. PMID: 34520831 Free article.
Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer-A Europe-Wide External Quality Assessment.
Erber R, Hartmann A, Fasching PA, Ruebner M, Stöhr R, Beckmann MW, Zentgraf M, Popp V, Weidler J, Simon I, Becker S, Huebner H, Fischer J, Guerini Rocco E, Viale G, Cayre A, Penault-Llorca F, Caniego Casas T, Pérez-Miés B, Palacios J, Jank P, Denkert C, Khoury L, Mairinger T, Ferrazzi F. Erber R, et al. Among authors: jank p. Cancers (Basel). 2021 Sep 21;13(18):4718. doi: 10.3390/cancers13184718. Cancers (Basel). 2021. PMID: 34572945 Free PMC article.
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status.
Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A, Müller V, Taube E, Fasching P, Schmitt WD, Marmé F, Stickeler E, Sinn BV, Jank P, Schem C, Klauschen F, van Mackelenbergh M, Denkert C, Loibl S, Capper D. Jurmeister P, et al. Among authors: jank p. Clin Epigenetics. 2021 Oct 3;13(1):184. doi: 10.1186/s13148-021-01176-5. Clin Epigenetics. 2021. PMID: 34602069 Free PMC article.
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
Jank P, Lindner JL, Lehmann A, Pfitzner BM, Blohmer JU, Horst D, Kronenwett R, Denkert C, Schmitt WD. Jank P, et al. Breast Cancer Res Treat. 2022 Jan;191(2):327-333. doi: 10.1007/s10549-021-06415-0. Epub 2021 Nov 16. Breast Cancer Res Treat. 2022. PMID: 34783927 Free PMC article.
53 results